氯氮平与去甲氯氮平同泮托拉唑的药动学相互作用
本研究为随机开放标签交叉试验,纳入12名健康志愿者,比较单用氯氮平12.5 mg与先服泮托拉唑40 mg连续5天后再用氯氮平的药动学。结果泮托拉唑使氯氮平生物利用度降低8.7%、Cmax与AUC(0-8)分别降低8.9%与9%,去甲氯氮平Cmax与AUC(0-8)分别降低8.2%与8.5%。作者认为机制为胃酸度影响吸收而非代谢酶,低剂量下无临床相关性,但解读TDM时需考虑合用抑酸药。
要点
- 泮托拉唑使氯氮平及去甲氯氮平暴露轻度下降,机制为胃酸度影响吸收。
- 低剂量氯氮平下该相互作用无临床相关性。
- 解读氯氮平TDM结果时应考虑是否合用抑酸药。
核心结论
- 合用泮托拉唑降低氯氮平与去甲氯氮平暴露,机制为影响胃酸度与氯氮平吸收而非代谢酶。
- 该相互作用在低剂量下无临床相关性,但解读氯氮平TDM结果时应考虑合用抑酸药。
研究设计与样本
- 随机开放标签交叉研究,纳入12名健康志愿者。
- 两阶段分别单用氯氮平12.5 mg,或先连续5天每日泮托拉唑40 mg(氯氮平给药前4天开始)后再用氯氮平12.5 mg,洗脱期至少2周。
- 给药后30 min、1、2、3、5、8 h共采集144份样本,用经验证的HPLC-UV法测定氯氮平与去甲氯氮平浓度。
主要发现
- 泮托拉唑组氯氮平生物利用度降低8.7%。
- 泮托拉唑组氯氮平Cmax降低8.9%(95%CI 6.7%-11.0%),AUC(0-8)降低9%(95%CI 7.2-10.8%)。
- 泮托拉唑组去甲氯氮平Cmax降低8.2%(95%CI 6.3%-10.2%),AUC(0-8)降低8.5%(95%CI 7.3%-9.7%)。
- 两组去甲氯氮平AUC(0-8)与氯氮平AUC(0-8)比值无显著差异。
临床怎么用
- 对合用抑酸药(如泮托拉唑)的患者,解读氯氮平TDM结果时需考虑暴露可能轻度降低。
- 低剂量氯氮平下该相互作用无临床相关性,无需常规调整剂量。
局限性
- 研究为健康志愿者单次给药的交叉试验,样本量12例。
- 仅评估单次低剂量氯氮平12.5 mg与泮托拉唑40 mg的相互作用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Clozapine is the first-line treatment for resistant schizophrenia. However, clozapine concentrations should be monitored, especially in the case of drug-drug interactions. The current work aimed to assess the clozapine interaction with pantoprazole. METHODS: This was a randomized open-label crossover study involving 12 healthy volunteers. The participants received a single dose of clozapine 12.5 mg in the two phases of the study alone or following five daily doses of pantoprazole 40 mg to be started 4 days before the clozapine dose, separated by a minimum of 2-week washout period. 144 samples were collected at 30 min, 1, 2, 3, 5 and 8 h following a single dose of clozapine 12.5 mg. The clozapine and norclozapine concentrations were determined using a validated HPLC-UV protocol. RESULTS: The pantoprazole treatment group had 8.7% lower clozapine bioavailability and lower maximum concentration (Cmax) and area under the curve (AUC(0-8)) by 8.9% (95% confidence intervals [95% CI], 6.7%-11.0%) and 9% (95% CI, 7.2-10.8%), respectively, as well as significantly lower norclozapine Cmax and AUC(0-8) by 8.2% (95% CI, 6.3%-10.2%) and 8.5% (95% CI, 7.3%-9.7%), respectively. However, no significant difference was found in the norclozapine AUC(0-8) to clozapine AUC(0-8) ratio between the two treatment groups. CONCLUSIONS: The concurrent intake of pantoprazole decreased the clozapine and norclozapine exposure, which was explained by the pantoprazole's impact on gastric acidity and clozapine absorption rather than on metabolizing enzymes. The interaction was not clinically relevant at low doses; however, clinicians should consider concomitant acid-reducing agents when interpreting clozapine therapeutic drug monitoring results.
引用
- Albitar O, Harun SN, Ghadzi SMS, et al. Clozapine and norclozapine pharmacokinetic interaction with pantoprazole. Br J Clin Pharmacol. 2026. PMID: 41536008. doi:10.1002/bcp.70450
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。